Navigation Links
DermTech's Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
Date:11/15/2011

LA JOLLA, Calif., Nov. 15, 2011 /PRNewswire/ -- DermTech, a biotechnology company developing non-invasive molecular diagnostics for disease detection, announced  it will present results from a study showing that its novel melanoma biomarker can be used with a high-throughput, low-cost qRT-PCR platform.  Strong earlier results using microarrays have been recapitulated on a qRT-PCR system that successfully discriminated melanoma with 100% sensitivity and 85% specificity.  Data will be reported at an oral presentation and during a poster session on November 17 at the Association for Molecular Pathology 2011 annual meeting in Grapevine, Texas.

DermTech's MelDTect™ melanoma detection test is based on the Epidermal Genetic Information Retrieval (EGIR®) approach that employs a patented adhesive-based method to obtain cells from the upper layer of the skin and genetic analysis to determine the probability of disease.  

"We saw exciting results using microarrays in our discovery work (Wachsman et al., British Journal of Dermatology, April 2011) and are pleased to report that our breakthrough approach to detecting melanoma is on course for clinical validation," said Sherman Chang, PhD, Senior Director of Molecular Biology. "Thus far in terms of accuracy, these data are better than any known detection product or products in development."

The study to be presented evaluated the suitability of a potential gene expression analysis platform along key parameters, including sensitivity, reproducibility, cost, linear dynamic range and throughput.  Using a qRT-PCR platform, it has been shown that the assays exhibited > 5-log linear dynamic range (LDR) and had a coefficient of variation (CV) < 3%.  Furthermore, 118 EGIR specimens (57 in situ and invasive melanomas, 61 nevi) were analyzed, and the 15-gene classifier was found to have an ROC AUC > 0.912 for discrimination of melanoma from nevi.

"The results, especially with respect to linear dynamic range, far exceed anything we've seen using microarrays and suggest that the non-invasive assay will perform extremely well in a high-volume clinical setting," said Bill Wachsman, MD, PhD, VA San Diego and UCSD, and a member of DermTech's Scientific Advisory Board.  "Since melanoma is highly curable if caught early, the goal is to develop a test that is highly sensitive, objective, and cost effective.  This assay meets these criteria and should be readily adopted."

DermTech's pre-validation study is expected to begin enrollment at clinical sites in Europe in early Q2 2012.  The study will evaluate use of the MelDTect test on a high throughput qRT-PCR platform in a broader population.

About DermTech:

Headquartered in La Jolla, California, DermTech is focused on the development of the company's patented Epidermal Genetic Information Retrieval (EGIR) technology.  The EGIR technology uses a custom adhesive tape to non-invasively and easily collect cells from the stratum corneum, i.e., the upper layer of the skin. The RNA from these cells is then isolated, amplified and analyzed using molecular biology tools to determine genetic profiles to be used for a range of applications including: non-invasive disease detection, personalized medicine and pharmaceutical R&D.  DermTech is actively pursuing research in the areas of melanoma, prostate cancer and other diseases and a number of skin conditions.  For additional information visit: www.dermtech.com.

About Melanoma:

Since 1930, there has been a 2000 times increase in the lifetime risk of developing melanoma.  By 2010, current estimates indicate 1 out of 50 people will be diagnosed with melanoma during their lifetime. (1)   Melanoma is the most common cancer in women aged 25-29.  5% to 10% of cases of cutaneous melanoma are the result of hereditary genetics in first-degree relatives. (2)   Unlike most other cancers, melanoma only infrequently responds to treatment and those available are highly toxic, impact quality of life.(3) If melanoma is treated before it spreads, it is 99% curable. (4)    The ten-year survival rate for melanoma patients whose disease is detected and treated at the earliest stages is 95-99% but drops to less then 5% if for a Stage 4 melanoma (invasive).(5)

  1. CA Cancer J Clin 2008
  2. Karolinska Institute, Aug 2008
  3. NCI Melanoma Treatment Options
  4. AAD Fact Sheet 2007
  5. American Joint Committee on Cancer – AJCC.  

Contacts:

DermTech
Jennifer Larson
415.725.2017
jlarson@dermtech.com


'/>"/>
SOURCE DermTech
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Auxogyn Licenses Non-invasive Embryo Assessment Technology From Stanford University
2. Dr. Suresh Koneru Introduces Zeltiq Non-Invasive Procedure For Fat Reduction
3. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
4. FDA Approves Label Change for Non-Invasive Fibroid Treatment
5. Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide
6. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
7. Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma
8. Arthritis drug could help beat melanoma skin cancer
9. Melanoma transcriptome reveals novel genomic alterations not seen before
10. U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma
11. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
Breaking Biology News(10 mins):